2022
DOI: 10.1111/dth.15591
|View full text |Cite
|
Sign up to set email alerts
|

Exclusively genital psoriasis successfully treated with Risankizumab

Abstract: Psoriasis is a chronic immune-mediated disease affecting 125 million people worldwide. 1 At least 65% of psoriasis patients experience an episode of genital psoriasis 2 but exclusively genital localization is rare (2%-5% of all patients). 3 About two thirds of patients report that they have never applied therapies and often there is no discussion of a specific strategy of treatment for the site traditionally considered difficult to treat. 2 Genital psoriasis has a deleterious impact on quality of life, is ofte… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 11 publications
0
2
0
Order By: Relevance
“…6,7 However, specific experiences on the treatment of genital psoriasis with risankizumab are scant and have a short follow-up. [8][9][10] We conducted a retrospective, 'real-world' study, with a 1-year follow-up, on risankizumab in the treatment of genital psoriasis. Consecutive adult (≥18 years) patients with moderate-to-severe plaque psoriasis involving the genital area and treated with risankizumab (150 mg administered subcutaneously at weeks 0, 4 and every 12 weeks thereafter) were enrolled.…”
mentioning
confidence: 99%
“…6,7 However, specific experiences on the treatment of genital psoriasis with risankizumab are scant and have a short follow-up. [8][9][10] We conducted a retrospective, 'real-world' study, with a 1-year follow-up, on risankizumab in the treatment of genital psoriasis. Consecutive adult (≥18 years) patients with moderate-to-severe plaque psoriasis involving the genital area and treated with risankizumab (150 mg administered subcutaneously at weeks 0, 4 and every 12 weeks thereafter) were enrolled.…”
mentioning
confidence: 99%
“…by Ceccarelli et al 1 It is well known that some areas are more difficult to treat than others and it is surely important to report the efficacy of an IL-23 inhibitor in such sensible localizations, like genitals. Indeed, only a few real-life studies investigated the efficacy of risankizumab on difficult sites (scalp, nails, genitals, and folds), showing that the involvement of genitals seems not to affect the achievement of PASI90 and PASI100.…”
mentioning
confidence: 99%